Atara Biotherapeutics Announces Two Presentations at 59th American Society of Hematology Annual Meeting, Including Positive Interim Results from a Multicenter Expanded Access Study of ATA129 for Patients with Epstein-Barr Virus (EBV)-Associated Cancers Nov 01, 2017 9:00am EDT
Atara Biotherapeutics Receives Rare Pediatric Disease Designation from FDA for ATA230 for Treatment of Congenital Cytomegalovirus (CMV) Infection Oct 26, 2017 8:00am EDT
Atara Biotherapeutics Announces Six of Ten Progressive Multiple Sclerosis (MS) Patients Experienced Clinical Improvements in an Ongoing Phase 1 Study of Autologous ATA190 Oct 25, 2017 8:00am EDT
Atara Biotherapeutics Initiates 60 Patient, Global Phase 1 Clinical Study to Evaluate Allogeneic ATA188 in Patients with Progressive or Relapsing-Remitting Multiple Sclerosis (MS) Oct 19, 2017 8:00am EDT
Atara Biotherapeutics Announces Abstract Publication for Two MSParis2017 Congress Presentations, Including Updated Interim Results from a Phase 1 Study of Autologous ATA190 in Patients with Progressive Multiple Sclerosis (MS) Oct 16, 2017 8:00am EDT
Atara Biotherapeutics Receives Positive Health Canada Regulatory Feedback for ATA129 Sep 11, 2017 8:00am EDT
Atara Biotherapeutics Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4) Aug 22, 2017 4:35pm EDT
Atara Biotherapeutics Expands Leadership Team with the Appointment of Dr. Kanya Rajangam as Senior Vice President and Chief Medical Officer Aug 22, 2017 8:00am EDT
